Board of Fellows

The Board of Fellows, composed of distinguished individuals and thought leaders from around the world, offers strategies and recommendations on a broad range of topics with critical relevance to the overarching leadership of Stanford Medicine. Fellows give guidance on nurturing a culture of innovation; executing on our Precision Health strategic vision and measuring that progress; and balancing and achieving synergies between and among our academic medical center's tripartite mission of research, training and patient care.


Sue Siegel


Sue Siegel has driven game-changing ideas and powered companies that advance industries and improve lives for more than three decades. As GE’s Chief Innovation Officer and CEO of GE Ventures for seven years, Sue oversaw investment in startups, creating and scaling new companies, and commercializing GE’s intellectual property. She also led strategy planning and oversaw the global marketing function.

Before joining GE, Sue was a General Partner at Mohr Davidow Ventures, where she spearheaded investments in personalized medicine, digital health and life sciences. Prior to becoming a venture capitalist, Sue led Affymetrix as President and a board member. She also held executive leadership roles at Bio-Rad, DuPont and Amersham after transitioning to a corporate career from early work in molecular biology and biochemistry.


Valued for her business insights and science background, Sue has served as a board member for more than a dozen companies, including Pacific Biosciences, Crescendo Biosciences and Navigenics. She is currently a board member at Align Technologies (ALGN), Illumina (ILMN), MIT’s The Engine, and KFF. Additionally, her advisory board appointments include Harvard Partners Healthcare Innovation and RAND Health Care.

Sue has also served on numerous nonprofit boards, including Silicon Valley’s Tech Museum of Innovation and Stanford Hospital and Clinics. She was a founding member of the NIH’s National Center for Advancing Translational Sciences and served on President Obama’s Precision Medicine Initiative Working Group.

Sue has been recognized in Fortune’s “34 Leaders Who Are Changing Health Care” and is an Aspen Institute Henry Crown Fellow. She is a featured “Multiplier” in the bestselling book: “Multipliers: How the Best Leaders Make Everyone Smarter.”


Elias Zerhouni, MD


Elias Zerhouni served as the President of Global Research and Development and as a member of the Executive Committee for Sanofi from January 2011 to July 2018.

His academic career was spent at the Johns Hopkins University and Hospital where he was Professor of Radiology and Biomedical Engineering and Senior Adviser for Johns Hopkins Medicine. Elias served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before serving as Director of the National Institutes of Health from 2002 to 2008. In that position, Elias oversaw the NIH’s 27 Institutes and Centers with more than 18,000 employees and a budget of $29.5 billion (2008).

In November 2009, President Barack Obama appointed him as one of the first presidential U.S. science envoys. Elias also served as senior fellow to the Bill and Melinda Gates Foundation from 2009 to 2010 and senior adviser to the CEO of Sanofi.


Elias has founded or co-founded five startup companies, authored more than 200 publications, and holds several patents. He has assumed positions on several boards, including most recently, those of the Lasker Foundation, Research America, and the NIH Foundation. He is also a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering.

Elias received the prestigious Legion of Honor medal from the French National Order in 2008, and was elected in 2010 as a member of the French Academy of Medicine and appointed as Chair of Innovation at the College de France in 2011.



Drew Altman, PhD


Drew Altman is President and CEO of the Henry J. Kaiser Family Foundation (known as KFF).  He is an innovator in the world of foundations and non-profits and a leading expert on national health policy who publishes and speaks widely on health issues.  He writes a regular column on health issues in Axios.

He founded the current-day KFF in the early 1990’s.  He is also founding publisher of KFF’s Kaiser Health News, the largest health newsroom in the U.S., distributing coverage of health issues through major news outlets across the country.


Dr. Altman was Commissioner of the Department of Human Services for the state of New Jersey, Director of Health and Human Services at the Pew Charitable Trusts, Vice President of the Robert Wood Johnson Foundation, and served in the Carter administration.  He is a member of the National Academy of Medicine and the Council on Foreign Relations and serves on numerous advisory committees.

Dr. Altman earned his Ph.D. in political science at MIT and completed his post-doctoral work at Harvard University before moving on to public service.  He holds an honorary doctorate from the Morehouse School of Medicine.


Linda Avey


Linda Avey is Co-Founder and CEO of, a personal health platform designed to close the information gap between health experts and consumers. By matching research and clinical insights to specific genetic markers, delivers targeted information to individuals, with the mission of expediting translation of relevant medical knowledge and facilitating Precision Health.

In 2006, Linda pioneered the field of consumer genetics with the co-founding of 23andMe, a leading personal genetic testing service. Previously, she spent 20 years in sales and business development in the biomolecular research industry. She helped develop genetics research programs for Affymetrix and Perlegen Sciences, leading to the first genome-wide association study of Parkinson's disease.


Linda is on the advisory board of Verily Life Sciences and is a board director of Perlara PBC. She was a founding independent board member of Rock Health, the first venture fund dedicated to digital health. 


Ernesto Bertarelli


Ernesto Bertarelli is a Swiss entrepreneur whose current business interests include Bertarelli Partners and B-FLEXION, a private, entrepreneurial investment firm that oversees growth-oriented operating businesses and asset managers. In 1996, Ernesto was appointed CEO of Serono S.A, the bio-pharma business grown over the course of three generations by his family. Under his leadership, Serono accelerated its move from pharmaceuticals to biotechnology, was listed on the New York Stock Exchange, and tripled its revenues. In 2007, Serono was sold to Merck KGaA.

Ernesto is a Chair of the Bertarelli Foundation, which is active in neuroscience research and marine conservation and science, and is a Co-Founder of the Campus Biotech life sciences hub in Geneva. He is chairman of the Harvard Medical School’s Board of Fellows and is a memeber of Harvard Business School’s Board of Dean’s Advisors. Between 2002 and 2009, Ernesto served as a board director of UBS AG.


Ernesto was awarded the Légion d’Honneur by the President of France and the Cavaliere di Gran Croce by the President of the Italian Republic. In 2000, he founded the sailing team Alinghi, which won the America’s Cup in 2003 and 2007. Born in Rome, Ernesto graduated from Babson College and earned an MBA from Harvard Business School.


Ray Bradford


With a passion to create more accessible, affordable, and consumer-friendly healthcare experiences with the help of technology, Ray Bradford founded Spruce Health in September 2013 and serves as the company’s Chief Executive Officer. Spruce is used by thousands of medical groups across America to modernize patient and care team communication and provide virtual care.

Prior to founding Spruce, Ray was a partner at Silicon Valley venture firm Kleiner Perkins Caufield & Byers (KPCB). He was responsible for multiple early-stage venture investments and teamed with the life sciences practice to identify ways technology could reshape the health care industry.  Before joining KPCB, Ray was an executive at and led product management for database services. At Amazon Web Services (AWS), he co-founded multiple new big data products, including Amazon Redshift.


Ray received his MBA from Stanford Business School, where he was an Arjay Miller Scholar. He earned his bachelor’s degree from Westminster College. He is a named inventor on multiple database patent applications and was included in Forbes’s “30 under 30” list in 2012. He continues to support other entrepreneurs as an active early-stage investor with investments in leading companies like Segment, Color Genomics, Looker, Ubiquity, Farmers Business Network, and more.


Robert A. Bradway


Robert A. Bradway is Amgen’s Chairman and Chief Executive Officer. Bob became Chairman in January 2013 and Chief Executive Officer in May 2012. Bob served as the company’s President and Chief Operating Officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London.

Bob holds a bachelor’s degree in biology from Amherst College and an MBA from Harvard University. He is a member of the board of directors of The Boeing Company. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university.


He is the Chairman of the CEO Roundtable on Cancer, a nonprofit organization comprised of executives founded to bring solutions to cancer treatment and prevention. He is a member of the American Heart Association CEO Roundtable, which is helping the association meet its goal of improving the cardiovascular health of all Americans.


Bill Brody, MD, PhD


An acclaimed physician-scientist, entrepreneur, and university leader, Bill Brody served as President of Johns Hopkins University from 1996 to 2009 and President of the Salk Institute from 2009 to 2015. Renowned for his achievements in biomedical engineering and the field of medical instrumentation, he is a member of the National Academy of Engineering and the National Academy of Medicine. He has authored more than 100 articles in medical journals, holds two patents in medical imaging, and is the Co-Founder of three medical device companies.

At the start of his career, Bill held appointments at the Stanford University School of Medicine, including Professor of Radiology and Electrical Engineering; Director of the Advanced Imaging Techniques Laboratory; and Director of Research Laboratories, Division of Diagnostic Radiology. In 1987, he moved to the Johns Hopkins University School of Medicine where he held several appointments, including the Martin W. Donner Professor of Radiology; Professor of Electrical and Computer Engineering; Professor of Biomedical Engineering; and Radiologist-in-Chief of the Johns Hopkins Hospital. Bill then served as provost of the Academic Health Center at the University of Minnesota.


Bill has been a national figure in efforts to encourage innovation and strengthen the U.S. economy through investments in research and education. He received his bachelor’s and master’s degrees in electrical engineering from MIT. He earned his doctorate and his medical degree from Stanford University. He continued his postgraduate training in cardiovascular surgery and radiology at Stanford, the National Institutes of Health, and UCSF.


R. Martin Chavez


R. Martin (“Marty”) Chavez, Ph.D. is a partner and vice chairman of Sixth Street Partners, where he works on research and development; diversity, equity, and inclusion; the sourcing engine; and the More Than Capital business, driving deeper engagement with the portfolio companies. Before joining Sixth Street, Marty served in a variety of senior roles at Goldman Sachs, including Chief Information Officer, where he oversaw the firm’s 9,000 engineers; Chief Financial Officer; and global co-head of the firm’s Securities (now Global Markets) Division. Marty was also a partner and member of the Goldman Sachs management committee.

Marty chairs the Board of Directors of Recursion, a digital biology company industrializing drug discovery by harnessing the power of cloud-based machine learning models. He advises numerous other companies, including, a leading blockchain developer; Cambrian Biopharma, a distributed drug discovery company developing medicines to extend healthy lifespans; Earli, which delivers new technologies for identifying and localizing early-stage cancers; and Ketch, which delivers responsive infrastructure for compliance and data security.


Marty serves as an advisor or board member to Abacus.AI, an AI startup developing new approaches to deep learning; the global bank, Grupo Santander, where he chairs the Board Innovation and Technology Committee; and the Digital Dollar Project, a partnership between Accenture and the Digital Dollar Foundation to advance exploration of a United States Central Bank Digital Currency.

Marty serves on the Board of Directors of the Los Angeles Philharmonic.

He holds an A.B. (1985) magna cum laude in Biochemical Sciences and an S.M. (1985) in Computer Science from Harvard, and a Ph.D. (1990) in Medical Information Sciences from Stanford.


Jonathan Coslet


Jonathan Coslet is the Chief Investment Officer of TPG Global. He is Chairman of TPG Capital’s Investment Committee and a member of the TPG Holdings Executive Committee. Jonathan joined TPG at its inception in 1993. Prior to joining TPG, he worked at Donaldson, Lufkin & Jenrette from 1991 to 1993 and at Drexel Burnham Lambert from 1987 to 1989 where he specialized in leveraged acquisitions.  

In 1991, Jonathan received his MBA from Harvard Graduate School of Business Administration, where he was a Baker Scholar and a Loeb Fellow. He received his B.S.E. in Economics (Finance) from the University of Pennsylvania Wharton School, where he was valedictorian, summa cum laude, a Gordon Fellow and a Steur Fellow.  


Jonathan also serves on the Strategy and Finance Committees of Stanford Children’s Hospital, the Stanford Medicine Advisory Council, the Stanford Institute for Economic Policy Research Advisory Board, the Investment Committee for Eastside Preparatory School, and as a Trustee for Menlo School. He also has previously served on the Board of Stanford Children’s Hospital, the Harvard Business School Board of Advisors, the Federal Reserve Bank of San Francisco Economic Advisory Council, and the Hamilton Project.


Trevor Fetter


Trevor Fetter is a Senior Lecturer on the faculty of Harvard Business School, where he teaches two required MBA courses. 

Before joining the faculty, he was Chairman and Chief Executive Officer of Tenet Healthcare Corp. Under his leadership, the company grew to $20 billion in revenues (Fortune ~#130) and employed 130,000 people. Tenet was one of the ~50 largest employers in the U.S. and had operations in more than 40 states and the United Kingdom.


In addition to teaching, Trevor is an active corporate director, advisor and investor. He currently serves as lead independent director of The Hartford Financial Services Group and serves on the boards of and is an investor in private healthcare services and healthcare technology companies Omada Health, TigerConnect, Trimedx Inc., and Regent Surgical Health. He is also a director of the Santa Catalina Island Company. Trevor’s serves on the board of the Catalina Island Conservancy, the Board of Fellows of Stanford Medicine, and the Smithsonian National Board.  At Harvard Business School, he has served on the board of dean’s advisors and the healthcare initiative advisory board.

Trevor received a bachelor’s degree in economics from Stanford University in 1982 and an MBA from Harvard Business School in 1986.  He is married to his Stanford classmate, Melissa Fetter, a community volunteer and proprietor of Beacon Hill Books and Café in Boston. Together they were honored with the 2017 Henry Cohn Humanitarian Award presented by the Anti-Defamation League. 


David Gluckman, MD


David Gluckman is Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. He has been with the firm since 1998, providing strategic and financial advice to senior executives and boards of directors at leading healthcare companies globally. Dr. Gluckman is a member of Lazard’s Global Executive Committee, North American Marketing Committee and Fairness Opinion Committee.


Dr. Gluckman is a member of the Advisory Board of the Vagelos Program in Life Sciences and Management, jointly administered by the College of Arts and Sciences and the Wharton School at the University of Pennsylvania. He is a member of the Board of Trustees of the Hackley School, and is Lazard’s representative in The Council of Foreign Relations, Corporate Leader Program.

Prior to joining Lazard, Dr. Gluckman was a practicing physician in Toronto, Canada where he founded, built and sold a multi-specialty medical clinic. Dr. Gluckman is a licentiate of the Medical Council of Canada and a member of the College of Physicians and Surgeons of Ontario.

University of Toronto, M.D. with Honors (Alpha Omega Alpha)

University of Pennsylvania, The Wharton School, M.B.A. with Distinction (Palmer Scholar)


André Hoffmann


André Hoffmann is the Vice Chairman of Roche Holding, Switzerland, a highly innovative pharmaceutical company and serves on the board of the fully owned subsidiary Genentech Inc. in California. Mr. Hoffmann has also contributed to the development and success of a data driven, cloud based, analytics company providing meaningful insights into the US health system: Inovalon Inc., based in Maryland.

Alongside his non-executive roles in the family business, André has a distinguished cursus in nature conservation and sustainability. He served on the board of WWF International for 19 years (the last 10 years as Vice President), Wetlands International, Global Footprint Network and FIBA.


He is the President of Fondation MAVA, and President of Fondation Tour du Valat in the Camargue, France.

He firmly believes in business as a force for good and has joined the board of SystemIQ in order to help positively disrupt critical economic systems. He is also a member of the Board of Trustees of the World Economic Forum, as well as of the Center for the Fourth Industrial Revolution in San Francisco.

André has been instrumental in establishing the Hoffmann Global Institute in Business and Society (HGIBS) at INSEAD, in Fontainebleau, France, his alma mater.

His philanthropic activity focuses on sustainable impact in many other organizations, mostly in the field of Education.

André studied economics at St. Gallen University and holds an MBA from INSEAD.


Charles-Antoine Janssen


Charles-Antoine Janssen is an impact investor focused on health care access. In 2012, Charles co-founded Kois, a global impact investing firm (blended finance structuring and asset management) active in health care, education/skilling, and living environments. He is a member of the investment committee of two Kois venture capital funds: HealthQuad (India health care delivery and technology innovations) and Tara IV (India health care and social entrepreneurship focus). He serves on the Board of the following private companies: Regency Hospitals, Medikabazaar, THB, Lilac Insights, TC4AI, GoJob, Trusted Family, and Imbra. He also serves on the Advisory Board of Quadria and Lighthouse. 

In 2001, Charles joined UCB (a CNS, immunology, and bone R&D-driven biopharma company). Among other responsibilities, he was Head of Global Business Development, General Manager of Austria and India, and managed International Major Markets Operations. He joined the Board of Tubize in 2011, the Board of UCB in 2012, and UCB’s Audit Committee in 2015. Charles worked for Merrill Lynch in London from 1996-2000 where he was Vice President of Equities Research, and then Vice President of New Derivatives, Europe.


Over the years, Charles has volunteered with several nonprofit organizations (UNHCR, MSF) and founded socially driven nonprofit organizations (Toolbox Belgium and Toolbox India). He is a member of the Board of Mind & Life Europe, a nonprofit organization aimed at building bridges between contemplative and contemporary sciences. He holds a bachelor of laws degree from Brussels University and completed the Advanced Management Program of Harvard Business School. Until his 2016 move to India, Charles was Assistant Professor of social entrepreneurship at the Solvay Brussels School of Management and Economics at Brussels University. 


Joe Jimenez


Joe Jimenez was CEO of Novartis from 2010 through 2018. Under his leadership, and driven by a commitment to R&D investment, Novartis developed one of the largest pipelines of self-originated drugs in the industry. Joe also transformed the company’s portfolio to focus on leading businesses with innovation power and global scale in pharmaceuticals, eye care, and generics.

Prior to serving as CEO of Novartis, Joe held the position of Division Head, Novartis Pharmaceuticals. He joined Novartis in 2007 as Division Head, Novartis Consumer Health. Previously, Joe served as President and CEO of the North American and European businesses for the H.J. Heinz Company. Additionally, he served on the Board of Directors of Colgate-Palmolive Co. from 2009 to 2015, and of AstraZeneca PLC from 2002 to 2007.


Joe is currently a member of the Boards of Directors of Procter & Gamble and General Motors. He received his bachelor’s degree from Stanford University and an MBA from the University of California, Berkeley.


Reed Jobs


Reed Jobs leads Emerson’s team in the health care space. With a sole focus on oncology, his team accelerates the discovery and translation of cancer research to best improve and empower the lives of patients. 

To achieve this, Reed is an active philanthropist and venture investor. His philanthropic portfolio includes several competitive grant programs with major research entities in the U.S. and the U.K. Additionally, he is involved in the creation of a nonprofit organization to house altruistically donated patient genomic and clinical data to be made available to researchers across the United States, upon request. 

He graduated Stanford University with an honors degree in history and international security before achieving a master’s degree in History. He is an avid traveler and distance runner.

Ann Huntress Lamont


Oak HC/FT Co-Founder & Managing Partner, Annie Lamont has more than 30 years of experience as a venture capitalist investing in transformative companies and entrepreneurs.

In 2014, Annie, along with Patricia Kemp and Andrew Adams, launched Oak HC/FT, a venture capital firm that invests in early to growth stage tech-enabled companies shaping the future of healthcare information and financial services. Before founding Oak HC/FT, Annie was a Managing Partner at Oak Investment Partners.


Annie is known as a leading healthcare and fintech investor, appearing on the Forbes Midas List, Institutional Investor’s list, and the Top 100 Venture Capitalist rankings published by CB Insights and The New York Times. She was the first recipient of the National Venture Capital Association’s award for Excellence in Healthcare Innovation. Annie was also honored with Healthcare Private Equity Association’s 2017 Russell L. Carson Award for lifetime achievement in healthcare investing.

She serves on the board of HCA, one of the world’s leading healthcare companies, and previously served on the Stanford Board of Trustees.

Annie received her bachelor’s degree in political science from Stanford University.


Clifton Leaf


Cliff Leaf became the 19th Editor-in-Chief of FORTUNE in March 2017 after serving as deputy editor for the previous three years. Prior to that he was a guest editor for the New York Times op-ed page, and held senior positions at the Wall Street Journal’s SmartMoney magazine and FORTUNE. He is also the author of the book, "The Truth in Small Doses: Why We’re Losing the War on Cancer—and How to Win It," which was named by Newsweek as one of “The Best Books About Cancer,” and which earned Cliff a Lifetime Achievement Award for cancer reporting from the European School of Oncology.

The founding chairman of the Brainstorm Health conference and a keynote speaker at more than three dozen scientific meetings around the world, Cliff has won numerous awards for his journalism and leadership in the anticancer effort, including the Gerald Loeb Award for Distinguished Business and Financial Journalism and the NIHCM’s Health Care Journalism Award. In 2006, Cliff delivered “Grand Rounds” at the National Cancer Institute in Bethesda, Maryland, becoming the first and only journalist to receive that honor.

Jillian Manus


Jillian Manus is Managing Partner of an early-stage Silicon Valley venture fund, Structure Capital. Branded “Architects of the Zero Waste Economy," they invest in underutilized assets and excess capacity. She is also the U.S Venture Advisor for the European Innovation Council. EIC is Europe’s largest innovation fund of £10b, investing in cutting edge deep tech to meet the UN’s sustainability goals by 2030.

Ms. Manus was named one of the top 25 early-stage Female Investors by Business Insider and is a TV business and political commentator for numerous media platforms including CNBC, Bloomberg and Sky. Manus serves on both corporate and non-profit boards, including: Stanford University School of Medicine Board of Fellows, NASDAQ Entrepreneurial Center Board of Directors, NYU Tisch School of the Arts and Communities in Schools. 


Prior to Structure Capital, Ms. Manus served as Co- Director of TMT for Credit Suisse Zurich, Director of Development for Universal and Warner Bros and Associate Publisher of the national publication Upside, reporting on the financial strategies of the technology industry.

Ms. Manus founded two companies, Broad Strategy, and Global Goal Management, Inc. She also co- hosts the business podcast “The Pitch." Ms. Manus attended The University of Oxford and New York University, where she served as a Trustee. She is also a recognized global public speaker. 


Michelle McMurry-Heath, MD, PhD


Dr. Michelle McMurry-Heath is the President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology organization.

BIO represents nearly 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to support companies that discover and deploy scientific breakthroughs that improve human heath, environmental stewardship, and sustainable agriculture.

Since assuming leadership of BIO on June 1, 2020, Dr. McMurry-Heath has positioned BIO as a leading champion of scientific innovation and the bio-revolution, which aims to use technological breakthroughs to cure patients, protect our climate, and nourish humanity. 


A common thread throughout McMurry-Heath’s career has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge advancements. She calls the distribution of scientific progress “the social justice issue of our age.”

Before coming to BIO, Dr. McMurry-Heath worked at Johnson & Johnson, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences.

Prior to her time at J&J, Dr. McMurry-Heath was a key science policy leader in government, including serving as the associate science director of the FDA’s Center for Devices and Radiological Health. McMurry-Heath was also the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program.

McMurry-Heath received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program.


Hemant Taneja


Hemant Taneja is a managing partner at General Catalyst and the Founder of the firm’s Silicon Valley operations. Hemant partners with founders who are building platform companies that are fundamentally aligned with the long-term interests of society.

He is an early investor in market-leading companies like Stripe, Gusto, Livongo, Samsara, Grammarly, Fundbox, and Snap. His investment thesis, known as “economies of unscale,” explains how 21st-century founders are leveraging modern platforms and AI-based mass personalization techniques to innovate across all major parts of the economy. In his recent book “UNSCALED,” Hemant builds on that thesis and articulates the need for accountability, transparency, and explainability as AI permeates every aspect of our daily lives.


He currently teaches a course on A.I., Entrepreneurship and Society at Stanford University that addresses these issues. In addition to his investment work, Hemant is the Co-Founder of Advanced Energy Economy, an organization focused on transforming energy policy in America; and is a Founding Board Member of Khan Lab School, an innovative K-12 school. Hemant holds five degrees from MIT. 


Christopher Viehbacher


Christopher A. Viehbacher joined Biogen as President and Chief Executive Officer and a member of the Board of Directors in November 2022.

Viehbacher has extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies and has a passion for advancing science for the benefit of patients and public health. 


After 20 years with GlaxoSmithKline, he served as global CEO of Sanofi for six years. Under Viehbacher’s leadership, Sanofi strengthened and diversified its R&D pipeline and delivered significant value to shareholders. 

More recently, Viehbacher and Ernesto Bertarelli co-founded Gurnet Point Capital, a Cambridge-based healthcare investment fund, which has led to the creation and continuing development of many innovative companies. He has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology.

Viehbacher has always been a strong advocate for innovation and public health. He has received a number of awards including the Légion d’Honneur from France.

He graduated from Queen's University in Kingston, Ontario, Canada. He is a certified public accountant, and he speaks French, German and English.


Emma Walmsley


Emma Walmsley has been GSK CEO and Board Director since April 2017.

Emma has been a member of GSK’s Leadership Team since 2011, as the President and then CEO of GSK Consumer Healthcare.

Prior to joining GSK in 2010, Emma worked with L’Oreal for 17 years in global and local marketing and general management roles in Paris, London, New York and Shanghai.


Emma joined the Microsoft board as an independent director in 2019. She was previously a Non-Executive Director of Diageo plc. She is a Member of the Stanford Medicine Board of Fellows.

Emma is a business advisor to the UK Prime Minister and a member of The Business Council Executive Committee in the US.

Emma ranked top in Fortune Magazine’s 2020 ‘Most Powerful International Women’.

Emma was appointed Dame Commander of the British Empire for services to the pharmaceutical industry and business in 2020.

Emma holds an MA in Classics and Modern Languages from Oxford University.


Robin L. Washington


Robin L. Washington is currently a member of the Board of Directors of Alphabet, Inc., Honeywell International, Inc., and She currently serves as chair of the leadership development and compensation committee for Alphabet and chair of the audit committee for

She is also a member of the President’s Advisory Group & Ross Business School Advisory Board, University of Michigan; the UCSF Benioff Children’s Hospital Oakland Board of Directors; a trustee of the Financial Accounting Foundation; and a board member of the Mastercard Foundation.


Ms. Washington served as Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc., from May 2008 – November 2019 where she oversaw Global Finance, Facilities and Operations, Investor Relations and the Information Technology organizations. Prior to Gilead, Ms. Washington was the Chief Financial Officer of Hyperion Solutions Inc. from 2005 –2007. She also served as Senior Vice President and Corporate Controller of PeopleSoft along with several other senior financial roles at the company from 1996 – 2005. Prior to PeopleSoft, Ms. Washington was Director of Finance for Tandem Computers, an Accounting Analyst for the Federal Reserve Bank of Chicago, and a Senior Auditor for Deloitte & Touche.

Ms. Washington is a certified public accountant and holds a bachelor’s degree in business administration from the University of Michigan and an MBA from Pepperdine University.


Matt Wilsey


Matt Wilsey is a Silicon Valley entrepreneur, angel investor, and start-up advisor. In addition to consumer products and services, Matt invests in and advocates for biomedical research, drug development, and genetic sequencing technologies. Currently, he is Chief Executive Officer of Grace Science, LLC and President of Grace Science Foundation. He became a “rare disease hunter” and advocate after his daughter Grace was born with NGLY1 Deficiency. He has since funded more than 200 scientists at 20 medical institutions in six countries with the sole purpose of treating the disease.

Matt spent many years as a front-line operator at CardSpring and Howcast and private equity professional at Kohlberg Kravis Roberts (KKR) on the Capital Markets team. Prior to that, Matt spent five years as Co-founder and Vice President of Business Development at Zazzle. He started his career serving in various roles at the White House and the Department of Defense.


Matt holds a BA from Stanford University and an MBA from Stanford’s Graduate School of Business. He is also a Trustee of the Charles and Helen Schwab Foundation and a Director of Perlara PBC.


Anne Wojcicki


Anne Wojcicki co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics.

23andMe has built one of the world's largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others.


Under Anne's leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology.


Joseph J. Wolk


Joseph J. Wolk (Joe) is the Executive Vice President and Chief Financial Officer for Johnson & Johnson. Joe serves as a member of company’s Executive Committee, playing a strategic role in the overall management of the organization and leading the development and execution of the business’ global long-term financial strategy. Additionally, as the financial steward of Johnson & Johnson, Joe’s scope of responsibilities includes driving competitive and profitable growth, generating sustainable cash flow, allocating capital to maximize value creation and managing risk across the entire enterprise.

Joe leads the worldwide Finance and Global Services organizations, which includes approximately 9,000 colleagues around the globe. He has been with Johnson & Johnson for 24 years, assuming the role of Chief Financial Officer in 2018.


Prior to assuming his current responsibilities, Joe was the Vice President of Investor Relations for Johnson & Johnson. In this role, he developed a winning strategy for building strong relationships with the investment community and disseminating Johnson & Johnson’s value creation narrative to all external financial stakeholders. During Joe’s tenure in this role, the Investor Relations function was regularly recognized by Institutional Investor as one of the best teams in the industry.

Prior to Investor Relations, Joe held a variety of senior leadership roles in several sectors and functions across the company, where he achieved superior results. He served as Vice President of Finance for the Pharmaceuticals Group, Vice President of Finance for the Medical Devices Global Supply Chain and Chief Financial Officer of the North America Pharmaceuticals Group.

Joe is an accomplished, Credo-based leader; passionate about talent development, driving innovation, and community service. He is the executive sponsor of Johnson & Johnson’s Impact Venture Fund, an “impact investment” fund that provides funding to entrepreneurs and their start-up companies or social enterprises to address healthcare challenges impacting people around the world. He is also the executive sponsor of the Veterans Leadership Council and a champion of the Finance Leadership Development Program. Additionally, he is a member of the Stanford Medicine Board of Fellows, the CNBC Global CFO Council and the Wall Street Journal CFO Network.

Joe holds a Bachelor of Science degree in Finance from St. Joseph’s University, where he serves on the University’s Board of Trustees and was recently inducted into the University’s Haub School of Business Hall of Fame for his excellence in business management. He earned his Juris Doctor degree from Temple University School of Law and is also a Certified Public Accountant (CPA).